Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone/Bupropion for Weight Regain Post Bariatric Surgery
NCT02616315Phase 4Withdrawn
- Sponsor
- Takeda
- Start
- Feb 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Placebo with Naltrexone HCl/Bupropion HCl (2 arms). Primary endpoint: Percent Change from Baseline in Body Weight at 26 weeks. Planned start Feb 2016; status: withdrawn.
02
Drugs
naltrexone + bupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02616315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616315.